Evidence map›Paper›PMID 41826855›Full record

ArticleBMC medical imaging2026

Jian Sun, Xiaohe Gao, Yanmei Li, Qingxia Wu, Jianwei Yang, Hongfei Zhao, Qingna Xing, Jie Chen, Zeying Wen

Abstract read
In one paragraph

Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jian Sun *Department of Nuclear Medicine, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450000, China.
Xiaohe Gao *Henan Province Hospital of Traditional of Chinese Medicine, Zhengzhou, 450000, China.
Yanmei LiPET/CT center, Henan Cancer Hospital, Zhengzhou, 450003, China.
Qingxia WuBeijing United Imaging Research Institute of Intelligent Imaging, United Imaging Healthcare Group, Beijing, 100089, China.
Jianwei YangPET/CT center, Henan Cancer Hospital, Zhengzhou, 450003, China.
Hongfei ZhaoDepartment of Nuclear Medicine, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450000, China.
Qingna XingDepartment of Radiology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Jie ChenDepartment of Ultrasound Medical, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450000, China. 15890003380@163.com.
Zeying WenDepartment of Nuclear Medicine, The First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450000, China. 15981890106@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aims to explore the value of PET/CT radiomics in differentiating low grade (grades 1/2) from grade 3 A of follicular lymphoma (FL) by constructing machine learning models, providing a non-invasive approach for pathological grading of FL.

methodsA total of 89 patients with pathologically confirmed FL were enrolled in this study, all of whom underwent PET/CT scans before treatment. They were grouped into two categories according to histopathological grades: those pathologically diagnosed with grade 1 and grade 2, and those pathologically diagnosed with grade 3 A. The regions of interest (ROIs) of CT and PET images were segmented by two experienced nuclear medicine physicians in the open-source and free LIFEx software, and radiomics features were extracted on the uAI platform. The dimensions of radiomics features were reduced by correlation coefficients and the least absolute shrinkage and selection operator (LASSO) regression methods, while clinical variables including PET/CT-derived parameters and clinical risk factors were selected through univariate and multivariable logistic regression. Based on the selected features, three radiomics models were constructed using logistic regression (LR), support vector machine (SVM), and random forest (RF) classifiers to differentiate low-grade from grade 3 A FL via a fivefold cross-validation strategy. Additionally, combined models using the same classifiers were built by integrating clinical features with radiomics features. The performances of such models were assessed with receiver operating characteristic (ROC) curve and decision curve analysis (DCA).

resultsIn total, 2264 PET/CT radiomics features were extracted from 89 patients and 7 optimal features (including 4 of CT features and 3 of PET features) were ultimately identified for the establishment of three radiomics models. Of the three radiomics models, the LR model performed the best in the validation cohort [area under the curve (AUC) = 0.858, sensitivity = 0.775, specificity = 0.755, accuracy = 0.763].

conclusionThe PET/CT-based radiomics had good predictive value for FL pathological classification, which can be served as a noninvasive reference tool for gold-standard biopsy to evaluate the severity of FL.

Indexed as

Lymphoma, FollicularPositron Emission Tomography Computed TomographyAdultAgedDiagnosis, DifferentialFemaleFluorodeoxyglucose F18HumansMachine LearningMaleMiddle AgedNeoplasm GradingRadiomicsRadiopharmaceuticalsROC CurveSensitivity and SpecificityFluorodeoxyglucose F18Radiopharmaceuticals18F-FDG PET/CTFollicular lymphomaPathological gradeRadiomics

Identifiers

PMID41826855
PMCPMC13141378

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.